MAXAIR
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXAIR is a metered-dose aerosol inhaler approved in 1992 for inhalation use. The specific indication and mechanism of action are not publicly detailed in available data, limiting clinical context. As a long-established inhaled product, it likely serves a maintenance or rescue respiratory function.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature, potentially contracting team focused on generic transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXAIR offers limited growth career opportunities due to its LOE-approaching lifecycle and zero linked job openings. Roles on this product are primarily defensive—focused on generic transition, authorized generic launches, cost optimization, and market share preservation rather than innovation or expansion.
Brand Manager (Generic Transition Lead)Senior Sales Representative
Worked on MAXAIR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.